Clovis Oncology, Inc. (CLVS) financial statements (2022 and earlier)

Company profile

Business Address 5500 FLATIRON PARKWAY
BOULDER, CO 80301
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments143240297520564266529
Cash and cash equivalents143240162222464216279
Short-term investments  13529810050250
Receivables27272113601
Inventory, net of allowances, customer advances and progress billings1431272728  
Inventory1431272728  
Prepaid expense2444263
Other current assets129199878
Other undisclosed current assets    20 (1)
Total current assets:198311366572627279540
Noncurrent Assets
Inventory, Noncurrent11010498114   
Property, plant and equipment7121527445
Intangible assets, net (including goodwill)1231291261158578161
Goodwill63636363655759
Intangible assets, net (excluding goodwill)606663522021102
Regulated entity, other noncurrent assets7      
Other noncurrent assets161923232028
Other undisclosed noncurrent assets13304012   
Total noncurrent assets:27529530329110885174
TOTAL ASSETS:473606670864735365713
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities78727496413023
Accounts payable27273229151111
Accrued liabilities51454268261911
Debt 64     
Other undisclosed current liabilities47495930403553
Total current liabilities:125185133126826676
Noncurrent Liabilities
Long-term debt and lease obligation437435645575282281 
Long-term debt, excluding current maturities437435645575282281 
Liabilities, other than long-term debt, including: 22164157
Deferred revenue and credits411
Deferred tax liabilities, net   31
Business combination, contingent consideration, liability      25
Other undisclosed liabilities, other than long-term debt 2216   
Other undisclosed noncurrent liabilities19014364  20280
Total noncurrent liabilities:626579711591286303337
Total liabilities:752764844717368368413
Stockholders' equity
Stockholders' equity attributable to parent(279)(159)(174)146368(4)301
Common stock0000000
Additional paid in capital2,6422,4982,1142,0341,8871,1751,130
Accumulated other comprehensive loss(43)(44)(45)(45)(42)(48)(47)
Accumulated deficit(2,877)(2,613)(2,244)(1,843)(1,477)(1,131)(782)
Total stockholders' equity:(279)(159)(174)146368(4)301
TOTAL LIABILITIES AND EQUITY:473606670864735365713

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues14916514395560 
Revenue, net560 
Cost of revenue(41)   (1)(0) 
Cost of goods and services sold    (1)(0) 
Gross profit:10816514395540 
Operating expenses(333)(467)(520)(429)(293)(373)(377)
Other undisclosed operating income    10 
Operating loss:(226)(302)(377)(334)(238)(373)(377)
Nonoperating expense(39)(68)(22)(34)(112)(8)(5)
Foreign currency transaction gain (loss), before tax(3)(0)(1)(0)(0)(1)3
Other nonoperating income0168410
Interest and debt expense(34)(35)18(3)(10)(8)(8)
Loss from continuing operations before equity method investments, income taxes:(299)(405)(380)(370)(360)(390)(390)
Other undisclosed income (loss) from continuing operations before income taxes3435(18)31088
Loss from continuing operations before income taxes:(265)(370)(399)(367)(350)(381)(382)
Income tax expense (benefit)01(2)(1)43229
Net loss available to common stockholders, diluted:(265)(369)(400)(368)(346)(349)(353)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(265)(369)(400)(368)(346)(349)(353)
Other comprehensive income (loss)11(0)(2)5(0)(23)
Comprehensive loss, net of tax, attributable to parent:(264)(369)(401)(370)(341)(349)(376)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: